• Marc-Alexander Mahl appointed to the Fresenius Management Board; Mahl succeeds Pierluigi Antonelli and will be responsible for the Fresenius Kabi businesses
• Fresenius CFO Sara Hennicken’s contract extended for another five years
• Sébastien Guery assumes overall responsibility for the Nutrition business at Fresenius Kabi
• Leadership team set for the next phase of #FutureFresenius

The Supervisory Board of Fresenius has unanimously appointed Dr. Marc-Alexander Mahl (58) to the Fresenius Management Board, effective November 1, 2026. He will be responsible for the Fresenius Kabi businesses. Mahl succeeds Pierluigi Antonelli, who is leaving the company for personal reasons. At the same time, the Supervisory Board has extended the contract of Chief Financial Officer (CFO) Sara Hennicken (46) for another five years. Her contract will therefore run until 2032.

“On behalf of the Supervisory Board, I would like to thank Pierluigi Antonelli for our successful collaboration built on mutual trust. Thanks to the consistent implementation of #FutureFresenius at Fresenius Kabi, all businesses are now excellently positioned in their respective growth markets and make a significant contribution to the company’s success. We wish Mr. Antonelli all the very best in his future endeavors,” said Wolfgang Kirsch, Chairman of the Supervisory Board of Fresenius. He added: “At the same time, I am delighted that in Marc-Alexander Mahl we have been able to bring an accomplished physician and experienced executive with more than 20 years of leadership experience at Fresenius to the Group Management Board. He is already responsible for two strategically important businesses, Pharma and Nutrition, and has played a key role in shaping their strategic direction as part of #FutureFresenius. The focus now is on consistently expanding the Biopharma, MedTech and Nutrition growth vectors. We very much look forward to working with him in his expanded role and are confident that he will continue the growth trajectory of all Fresenius Kabi businesses.”

Marc-Alexander Mahl will continue to lead the Pharma Business Unit. Given its growing strategic importance, the Nutrition business will in future be managed as a standalone Business Unit under the leadership of Sébastien Guery. Guery has been responsible for the Nutrition business since April 2024 and previously held several management positions at other international companies, including Sandoz, DuPont Nutrition & Biosciences and McKinsey. In his expanded role, Guery will report directly to Marc-Alexander Mahl, who is responsible for the Fresenius Kabi businesses on the Fresenius Management Board.

At the same time, the Supervisory Board has extended the contract of CFO Sara Hennicken for another five years. Her contract will now run until 2032. “Sara Hennicken has played a pivotal role in shaping the successful execution of #FutureFresenius from the very beginning. Thus, we very much look forward to continuing our successful collaboration with her,” said Kirsch.

“I would like to congratulate Sara Hennicken and Marc-Alexander Mahl and very much look forward to continuing our work together on the Management Board. On behalf of the Management Board, I would also like to thank Pierluigi Antonelli for the excellent collaboration over the past years and wish him all the very best for the future. Looking ahead, the medical nutrition business will play an even more important role for the company as a whole. I am therefore very pleased that Sébastien Guery will now assume overall responsibility for the Nutrition business,” added Michael Sen, Chief Executive Officer of Fresenius.

Leadership team set for the next phase of #FutureFresenius
With these decisions and the further strengthening of its operating businesses, Fresenius is putting its leadership team in place for the next phase of #FutureFresenius and underscoring its ambition to create sustainable value through profitable, innovation-driven growth.

Dr. Marc-Alexander Mahl has headed Fresenius’ Pharma and Nutrition businesses since May 2023. In addition, he oversees sustainability activities in these businesses. Mahl has been with Fresenius since July 2001, with a brief interruption, and has since held various management positions with regional and global responsibilities. Since 2011, he has been responsible for the global Pharma business. In parallel, Mahl served as President of Medicines for Europe and as a member of the Executive Committee of the German industry association for specialized nutrition. Mahl studied medicine, is a specialist in transfusion medicine and holds an MBA from INSEAD.

Sara Hennicken has been Chief Financial Officer of Fresenius since September 2022. In this role, she is responsible for Finance, IT and Cybersecurity. She joined the company in 2019 as Senior Vice President Global Treasury & Corporate Finance for Fresenius and Fresenius Medical Care. Prior to that, she spent 14 years in investment banking, most recently serving as Managing Director at Deutsche Bank. From 2005 to 2010, Hennicken worked at Citigroup in Frankfurt and London. She studied economics in Germany and the United States.

# # #

Fresenius (XFRA: FRE, OTC: FSNUY) is a global, therapy-focused healthcare company dedicated to saving and improving human lives around the world. Through Fresenius Kabi and Fresenius Helios, the company delivers system-critical, innovative and affordable healthcare across the full continuum of care: Fresenius Kabi is a leading provider of lifesaving medicines, medical nutrition, and medical technologies for critically and chronically ill patients, reaching around 450 million people each year. Fresenius Helios is Europe’s largest private hospital operator, treating around 27 million patients annually.

With more than 178,000 employees and operating in more than 60 countries, Fresenius generated €22.6 billion in revenue in 2025.

For more information, visit www.fresenius.com and follow Fresenius on LinkedIn.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Wolfgang Kirsch

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Dr. Michael Moser, Dr. Christian Pawlu 
Chairman of the Supervisory Board: Wolfgang Kirsch

Press Contact:
Edith Müller-Callsen
Group Communications
Fresenius SE & Co. KGaA 
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
M +49 160 9968 4046
edith.mueller-callsen@fresenius.com

invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal

• Publication in Molecular Therapy Oncology reports Phase 1 data from 17 patients with advanced, treatment-refractory solid tumors
• Decentralized point-of-care manufacturing of APN401 was feasible across manufacturing sites
• APN401 demonstrated a favorable safety profile, with no dose-limiting toxicities or grade ≥3 treatment-related adverse events
• Disease stabilization was observed in 5 of 10 RECIST-evaluable patients

Vienna, Austria, 15 October 2026: invIOs GmbH (“invIOs”), a privately held biotechnology company developing innovative cancer immunotherapies, today announced the publication of new clinical data with its autologous PBMC (peripheral blood mononuclear cell) therapy APN401 in the peer-reviewed journal, Molecular Therapy Oncology. The publication, “Phase I Evaluation of APN401, an Autologous CBL-B–Silenced PBMC Therapy, in Advanced Solid Tumors”, reports findings from two Phase 1 studies evaluating APN401 in patients with advanced, treatment-refractory solid tumors.

A total of 17 patients received APN401 across three dose levels. The patients had advanced solid tumors and had received between two and eleven prior lines of systemic therapy. The treatment was well tolerated, with no dose-limiting toxicities, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or grade ≥3 treatment-related adverse events. The highest dose of 4.5 × 10⁷ PBMCs/kg was selected as the recommended Phase 2 dose.

Disease stabilization was observed in 5 out of 10 RECIST-evaluable patients. Exploratory immune profiling identified systemic changes following APN401 treatment, including increased levels of cytotoxic mediators and expansion of specific T-cell populations. These changes were most pronounced in patients with stable disease. This suggests that APN401 can enhance immune activity against the tumor and that this effect may be linked to clinical benefit.

APN401 is an autologous cell therapy utilizing patients’ own PBMCs in which the intracellular immune checkpoint CBL-B is transiently silenced using siRNA. CBL-B acts as a brake on the immune system: it negatively regulates antigen receptor signaling and T-cell activation. By temporarily reducing CBL-B activity in immune cells, APN401 cell therapy is engineered to overcome the immunosuppressive tumor microenvironment and attack tumor cells.

Romana Gugenberger, PhD, Managing Director of invIOs, commented: “We are thrilled to see our clinical data with APN401 published in a peer-reviewed journal. We are encouraged by the favorable safety profile, the disease stabilization observed, and the systemic immune changes following treatment. This is especially noteworthy considering that these patients had already received multiple prior lines of therapy. These results highlight the promise of CBL-B silencing as a new approach in immuno-oncology and demonstrate that our EPiC cell manufacturing platform can reliably produce cell therapies through a rapid, decentralized manufacturing process. Together, these findings support further clinical evaluation of APN401 and our EPiC platform as we work towards new treatment options for patients with difficult-to-treat solid tumors.”

APN401 is produced using invIOs’ proprietary EPiC® point-of-care platform, which allows for manufacturing of the cell therapy product with a vein-to-vein time of less than 24 hours. The study demonstrated reproducible manufacturing across sites and supported the feasibility of repeated administration.

About invIOs

invIOs is a privately held biotech company based in Vienna, Austria, focusing on the discovery and development of novel cancer therapies. The invIOs team applies its extensive knowledge of immune system activation to create personalized and targeted therapies for solid tumors. The company is progressing a pipeline of four programs that include both cell therapy and small molecule strategies. invIOs is also partnered with leading institutions and universities, including the Dana-Farber Cancer Institute, to co-develop treatments for glioblastoma. EPiC, invIOs’ proprietary cell therapy platform, allows the creation of personalized cell therapies based on localized processing of a patient’s fresh immune cells, enabling rapid treatment in an out-patient setting.

The platform’s lead asset, APN401, has successfully completed Phase 1 clinical trials in patients with various solid tumors. A second candidate, INV441, is currently being developed for glioblastoma and a first-in-human Phase 1 clinical trial is in planning. Additionally, INV451, the third EPiC-based program, represents a next-generation CAR-T cell approach targeting rare tumor types.

INV501 is a novel orally available small molecule candidate that can selectively enhance anti-tumor immune responses. It induces T-cell activation, proliferation, and tumor-specific cytotoxicity. INV501 has demonstrated favorable bioavailability and preclinical proof of concept with strong data in multiple solid tumor indications.

For further information, please visit www.invios.com and connect with us on LinkedIn.

Contacts

invIOs Romana Gugenberger, PhD Managing Director T +43 1 8656577 0 Email: investors@invios.com

MC Services AG Dr. Cora Kaiser, Dr. Regina Lutz T +49 89 210 228 0 US: Laurie Doyle T +1-339-832-0752 Email: invios@mc-services.eu

BIOTECH SUMMIT AUSTRIA Highlights Growing Momentum
Across Austria’s Biotech Sector

Innsbruck, Austria – October 15, 2026. The fourth BIOTECH SUMMIT AUSTRIA brought together leading voices from research, industry, startups, investment and policy in Innsbruck this week. Jointly organized by BIOTECH AUSTRIA, Human.technology Styria and Standortagentur Tirol, the summit serves as a national meeting point for Austria’s biotech sector with growing international participation and this year drew more than 250 participants from 12 countries.

Held under the motto “Start up, Scale up, Step up!”, the program reflected the journey from scientific discovery and company creation through financing and organizational growth to international expansion and long-term impact. Across the two-day agenda, keynotes, panel discussions, workshops and startup pitches explored the opportunities, challenges and next steps for Austria’s biotech community as it continues to grow and connect internationally.

Peter Llewellyn-Davies, President of BIOTECH AUSTRIA, commented: “Austria has a strong scientific foundation, but one decisive question is how we translate that strength into companies that can grow and compete internationally. This year’s summit brought together researchers, entrepreneurs, investors and policymakers who all play a role in making that transition possible. The discussions demonstrated the growing ambition of the Austrian biotech sector as well as the importance of continued collaboration to unlock its full potential. My thanks go to our speakers, participants, sponsors and co-hosts for making Innsbruck such a productive meeting point for the sector.”

The keynote program featured former STADA AG CEO Claudio Albrecht, who explored how geopolitical shifts, technological innovation, changing healthcare systems and new business models could shape the pharmaceutical industry through 2035. Karl Nehammer, Vice President of the EIB and former Federal Chancellor of Austria, addressed the conditions needed for European biotech innovators to grow and compete globally. Olympic sailing champion Lukas Mähr drew on his experience to explore resilience and teamwork, while Stefan Haubner, Founding Partner at APEX Ventures, considered whether European venture capital needs a model of its own. Further sessions addressed topics such as venture financing, global IP strategy, AI in biotech investment and Austrian biotech strategy and policy. The program concluded with a fireside chat between BioNTech founder and investor Christoph Huber and Peter Llewellyn-Davies, reflecting on experiences and lessons from building successful biotech ventures.

Anton Mattle, Governor of Tyrol, commented: “Biotechnology is an important driver of innovation and future economic development. Events such as the BIOTECH SUMMIT AUSTRIA showcase Tyrol’s strengths in life sciences and create valuable connections between science, business and policy. They also contribute to strengthening Austria’s international visibility and support the exchange of ideas and partnerships that help innovative companies grow.”

Networking and partnering remained a central element of the summit. Dedicated 1:1 meetings and social events gave participants from across the biotech value chain opportunities to establish new relationships, deepen existing connections and explore future potential collaborations beyond the conference sessions.

Marcus Hofer, CEO of Standortagentur Tirol and local host of the summit, and Lejla Pock, CEO of Human.technology Styria, added: “Bringing the summit to different regions allows us to showcase their individual strengths while fostering exchange and collaboration across Austria’s biotech community and beyond. Innsbruck provided an excellent setting for discussions, new connections and future partnerships. We look forward to building on this momentum when the summit moves to Graz in 2027.”

The fourth BIOTECH SUMMIT AUSTRIA concluded with a closing reception and a handover to the next host location: The discussions in Innsbruck reflected a sector that is gaining momentum, strengthening international connections and working together to translate scientific excellence into lasting economic and societal impact. The fifth BIOTECH SUMMIT AUSTRIA will take place in Graz on 21-22 October 2027.

For further information and to revisit highlights of the fourth BIOTECH SUMMIT AUSTRIA, please visit the BIOTECH SUMMIT AUSTRIA website.

For post-event inquiries and additional information, please contact:

BIOTECH AUSTRIA
Christine Llewellyn-Davies
Head of Operations
+43 670 6030601
Email: info@biotechaustria.org

Human.technology Styria
Lejla Pock
CEO
Eva Bucht
PR & Marketing
+43 699 188 99 708
Email: office@human.technology.at

Standortagentur Tirol
Marcus Hofer
CEO Standortagentur Tirol
Albert Bloch
Communication & Press
+43 676 843 101-270
Email: albert.bloch@standort-tirol.at

Media Contact

MC Services AG
Dr. Cora Kaiser, Dr. Johanna Kobler
+49 89 210 228 0
Email: biotechaustria@mc-services.eu

About BIOTECH AUSTRIA

Since December 2020, BIOTECH AUSTRIA has been the voice of the Austrian biotech industry, enabling and connecting a non-governmental ecosystem so that businesses can start, grow and deliver world-changing innovation. Life Sciences are a key industry in Austria, and biotechnology is one of the fastest-developing sectors with high growth dynamics and international competitiveness. BIOTECH AUSTRIA is constantly expanding its network with new members and supporters in order to gather even more expertise under one roof. BIOTECH AUSTRIA represents over 100 biotech and life science companies, from start-ups to big pharma, academic institutions, research institutes, organisations and service providers to the sector. More information can be found at www.biotechaustria.org or on LinkedIn.

About Human.technology Styria

Human.technology Styria GmbH (HTS) is a cluster organization founded in 2004 with a focus on Life Sciences. It operates in three strategic priority areas: Medical Technology, Pharmaceuticals & Biotechnology, and Health & Sustainability. Additionally, HTS is actively involved in cross-cutting topics such as Start-Ups, Digitalization, and Qualification. The cluster sees itself as a bridge-builder between research, development, and industry, aiming to create synergies, enable innovations, forge new partnerships, and enhance the national and international visibility of the region. Companies within the cluster community benefit from exclusive service offerings related to Contact Management, Business Development, Internationalization, Networking, Events, Communication, and Knowledge Transfer. Within the environment of the Styrian Life Science Cluster, there are 150 companies with 40,000 employees generating a turnover of 5 billion euros. Approximately one-third of this can be attributed to the Pharma/Biotech sector. More information can be found at www.humantechnology.at.

About Standortagentur Tirol / Health Hub Tirol

Tirol is a strong life sciences location. Successful companies and outstanding universities ensure a high research output, over 11,000 jobs and an industry turnover of almost 3 billion euros per year. Almost 100 innovative companies, institutions and universities are networked in the Cluster Life Sciences Tirol, which is based at the Standortagentur Tirol. In addition, the state of Tirol invests in a location development program for life sciences via Lebensraum Tirol Holding, which is implemented by Standortagentur Tirol and its subsidiaries. This program aims to drive innovation in the fields of medical technology, digital health, pharmaceuticals and biotechnology. Tirol is to be positioned as a top European life sciences region by 2030. One pillar of the program is the Health Hub Tirol, which works closely with the Cluster Life Sciences Tirol and Startup.Tirol to provide (lab) space and a wide range of startup services. More information can be found at www.standort-tirol.at and www.healthhub.tirol.

Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board

Will lead Evotec’s global scientific strategy and drive differentiation across its discovery and development services, technology platforms and proprietary innovation Brings more than 25 years of global experience in pharma, biotechnology and academia

Hamburg, Germany, October 15, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the appointment of Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board, effective November 1, 2026. Dr. Holbrook brings to Evotec more than 25 years of experience as both a scientist and R&D leader, applying novel technologies and data approaches to the challenges of drug discovery and advancing programs toward the clinic. Her experience spans multi-modal ‘omics, data science, novel therapeutic modalities and precision medicine, complemented by experience in commercializing innovative technologies, shaping drug discovery partnerships and leading therapeutic research portfolios. At Evotec, Dr. Holbrook will draw on recent scientific advances to help customers and partners discover and develop new medicines faster and with a higher probability of success.

Dr. Christian Wojczewski, Chief Executive Officer of Evotec, said:

“Joanna has a keen understanding of how data, AI and new technologies are transforming drug discovery and development today. She combines this forward-looking perspective with deep scientific expertise and a strong focus on generating robust, actionable results. I look forward to working with her as we continue to strengthen Evotec’s position as a leading partner for any organization that strives to bring new, groundbreaking medicines to market.”

Dr. Holbrook most recently served as Therapy Area Head, Cardiovascular, Renal and Hepatic Disease and Head of in vitro Discovery Platforms at Novo Nordisk. Prior to that she held positions at UK biotech companies Biomodal, where she served as Chief Scientific Officer, and BenevolentAI, where she was Vice President, Translational Medicine. She was also Professor of Bioinformatics at the University of Southampton and Senior Principal Investigator at the Singapore Institute for Clinical Sciences (A*STAR) and adjunct Professor at National University of Singapore. She started her career at GSK, where she held positions of increasing responsibility across therapy areas and bioinformatics. She holds a Ph.D. in Molecular Cell Biology from University College London and a B.Sc. in Genetics from the University of Newcastle.

Dr. Joanna Holbrook, Evotec’s incoming Chief Scientific Officer, added:

“Evotec has exceptional breadth of scientific expertise and capabilities spanning drug discovery, drug development and manufacturing. I am excited by the opportunity to work across the business to strengthen our scientific differentiation, build integrated solutions to the most important challenges in drug discovery, and develop new capabilities that are unique to Evotec.”

 

About Evotec SE

Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec’s global team of around 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.

 

Forward-looking statements

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

 

Investor Relations and Media Contact

Dr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.com

 

Heidelberg Pharma Reports on the First Nine Months of Financial Year 2026

• Phase IIa trial in multiple myeloma at the recommended Phase II dose (RP2D) of 175 µg/kg proceeding as planned
• NMPA approval for clinical trial of pamlectabart tismanitin (HDP-101) combination therapy in China
• Additional collaboration agreement signed with Huadong Medicine to jointly develop new Antibody Drug Conjugates
• New preclinical and clinical data presented at scientific meetings
• Financial figures in line with planning; Sales revenue and other income increased by 79% compared to previous year and cost reduction program successfully implemented with total cost savings of roughly 30%

Ladenburg, Germany, 15 October 2026 – Heidelberg Pharma AG (FSE: HPHA) reported today on its operational progress as well as on the Group’s financial figures for the first nine months of fiscal year 2026 (1 December 2025 – 31 August 2026).

Dr. Dongzhou Jeffery Liu, Chief Executive Officer of Heidelberg Pharma AG, commented: “The first nine months of fiscal year 2026 have been a period of important progress for Heidelberg Pharma. We have advanced the clinical development of our lead project HDP-101 (pamlectabart tismanitin), strengthened our financial position and rebuilt our early ADC pipeline through our strong strategic partnership with Huadong Medicine. In our lead program pamlectabart tismanitin, we have achieved a development milestone by obtaining the recommended Phase II dose (RP2D) of 175 µg/kg and are currently focused on advancing the clinical Phase IIa study in heavily pretreated multiple myeloma patients in Europe and the United States to generate further clinical data. Patient recruitment is progressing as planned, and we are seeing increased interest from investigators following the demonstration of a favorable safety profile and initial encouraging efficacy data for our Amanitin-based ADC. We are actively seeking potential partnerships with our three lead assets (clinical or clinical-ready stage) aiming to fast develop these drug candidates and demonstrate the clinical benefits to the cancer patients who need them.

At the same time, we are very proud to have recently received approval, together with Huadong Medicine, to conduct a combination study with pamlectabart tismanitin in China, which will be carried out by our partner.”

Peter Willinger, Chief Financial Officer of Heidelberg Pharma AG, commented: “We are convinced that the new collaboration agreement with Huadong will increase our added value and contribute to the future growth of the Company. Next to that our partner programs continue to progress as planned and generated milestone payments in the first nine months. Together with the royalty financing agreement with HealthCare Royalty and Soleus Capital, this reinforces our solid financial position and supports the confirmation of our 2026 financial guidance. Furthermore, the decrease in expenses is a result of the stringent cost savings in the last months, which will remain a focus in the future.”

Key operational developments within the company and among its partners

• Pamlectabart tismanitin (HDP-101) development program: Pamlectabart tismanitin (HDP-101), an Amanitin-based antibody-drug conjugate (ADC) targeting the BCMA antigen, is being tested in a Phase I/IIa open-label, multicenter study for the treatment of relapsed or refractory multiple myeloma, a cancer of the bone marrow. The Phase I dose escalation part of the clinical study was completed in April 2026, after treating ten patient cohorts across a dose range of 20 to 218 µg/kg. Heidelberg Pharma’s Benefit and Risk Assessment team agreed with the recommendation of the study’s Safety Review Committee (SRC), which had conducted a comprehensive review of safety, tolerability and pharmacokinetic (PK) data from the ongoing trial, and selected the dose level from Cohort 9 – 175 µg/kg – as Recommended Phase 2 Dose (RP2D).
  In the Phase I part of the study, 53 patients with relapsed or refractory multiple myeloma (RRMM) were dosed and included in the data analysis. All patients were heavily pretreated with a median of five prior lines of treatment. Pamlectabart tismanitin was well-tolerated and a maximum tolerated dose was not reached. All adverse events that occurred were reversible, and no treatment related grade 5 events were observed.
  In clinical Phase 1 study, clinical responses were observed from ≥90 µg/kg, with increasing efficacy at higher doses. Across Cohorts 5 – 9 (90 -175 µg/kg), the Overall Response Rate (ORR) was 42% (13 out of 31 evaluable patients), including seven partial responses (PR), three very good partial responses (VGPR), and three stringent complete responses (sCR). In Cohort 9 (175 µg/kg), two out of five evaluable patients achieved good response: one PR and one VGPR.
• New preclinical data from the ATAC technology platform presented at the AACR 2026 Annual Meeting: Heidelberg Pharma presented promising preclinical data from its Amanitin-based ADC HDP-103 targeting metastatic castration‑resistant prostate cancer (mCRPC) at the American Association of Cancer Research (AACR) Annual Meeting 2026 in April.
  HDP-103 demonstrated target-specific binding in human tissues and robust and durable antitumor activity in patient-derived xenograft (PDX) models. The potent anti-tumor efficacy of HDP-103, combined with a favorable half-life and a manageable safety profile, led to a comfortable therapeutic index (TI) of HDP-103 that is well in the range of other ADCs that are approved or in development for solid tumor indications. Taken together, these data warrant further clinical development of HDP-103 as a novel treatment option for mCRPC.
• Milestone payment from partner Takeda received: Partner Takeda has started clinical development of its ADC candidate (TAK-188), which utilizes the Amanitin-based ADC technology licensed from Heidelberg Pharma. With the dosing of the first patient in a Phase I/II clinical trial in patients with advanced or metastatic solid tumors, an agreed-upon development milestone was reached in January, triggering a payment to Heidelberg Pharma. Financial details were not disclosed.
• Milestone payment from partner Huadong received, programs on track: Strategic partner Huadong Medicine dosed the first patient in a clinical trial with pamlectabart tismanitin in China in March, hereby achieving an agreed-upon development milestone that triggered a payment to Heidelberg Pharma.
  The Phase I clinical trial will evaluate the safety, tolerability, pharmacokinetics and efficacy of pamlectabart tismanitin in Chinese patients with plasma cell disorders, including multiple myeloma. This bridging study is conducted in addition to the existing clinical program with this ATAC to ensure comparability of safety and efficacy across different populations. Dosing has been initiated at 140 µg/kg, a dose level previously shown to be safe and well tolerated in the Caucasian ethnicity.
  Furthermore, at the end of August it was announced that the China National Medical Products Administration (NMPA) has granted Clinical Trial Approval for a Phase Ib/II clinical trial evaluating pamlectabart tismanitin in combination therapy for the treatment of patients with relapsed/refractory multiple myeloma.
  This trial will evaluate the safety, tolerability, and preliminary efficacy of pamlectabart tismanitin in combination either with pomalidomide and dexamethasone, or with daratumumab and dexamethasone, in adult patients with relapsed/refractory multiple myeloma who have received at least one prior line of therapy. The trial will be conducted by Heidelberg Pharma’s partner Huadong Medicine in China who will bear the development cost.
• Additional collaboration agreement signed with Huadong Medicine to jointly develop new Antibody Drug Conjugates: Heidelberg Pharma and Huadong Medicine have broadened their existing partnership through joint research and development of new ADCs involving up to six targets. Under the agreement, the parties will combine and leverage their complementary technologies, expertise, and resources. This includes Heidelberg Pharma’s proprietary ATAC technology platform and other novel toxin payloads, together with Huadong’s state-of-the-art R&D capabilities. The partnership aims to create synergies and drive the development of innovative next-generation ADCs, including bispecific and multispecific ADCs.
  The new ADCs may incorporate proprietary antibodies or technologies from Huadong Medicine and may carry dual payloads. This combination is designed to improve the targeting precision and safety of the drugs, while enhancing biological efficacy and clinical benefits, thereby offering potentially transformative therapeutic options for patients with relapsed/refractory diseases. The agreement foresees that ownership of the resulting development candidates will be allocated between the partners, taking into account their respective contributions.
• Amendment to license agreement with HealthCare Royalty secures USD 20 million: In early March, a further amendment to the existing license agreement with HealthCare Royalty (HCRx), with the participation of Soleus Capital Management, L.P. (Soleus Capital), was signed. The amended agreement covers the partial monetization of Heidelberg Pharma’s future royalty payments from the global sale of Telix’s diagnostic imaging agent TLX250-Px (proposed trade name: Zircaix^®). In connection with the amendment, Heidelberg Pharma received USD 20 million from Soleus Capital upfront. An additional payment of USD 25 million from Soleus Capital will be due upon FDA approval of TLX250-Px.
  As part of the current contract extension, Heidelberg Pharma has agreed to an increase in the cap on total payments as well as certain other contractual amendments. Soleus Capital’s participation has no impact on the payment from HCRx upon FDA approval.
• Change in Executive Management Board: Chief Financial Officer Walter Miller left the Company at the end of April 2026 upon expiration of his contract and at his own request. Peter Willinger succeeded him as Chief Financial Officer effective 1 May 2026.

Events after the end of the reporting period

• New clinical data on pamlectabart tismanitin (HDP-101) presented at International Myeloma Society Annual Meeting 2026: At the Annual Meeting of the International Myeloma Society (IMS) in Glasgow, United Kingdom, in mid-September, Professor Marc Raab, Head of the Heidelberg Myeloma Center at Heidelberg University Hospital, Germany, presented new clinical data from ten patient cohorts in the ongoing study evaluating pamlectabart tismanitin in multiple myeloma. In cohorts 9 and 10, pamlectabart tismanitin consistently demonstrated a very good safety and tolerability profile. In Cohort 9 (175 µg/kg), encouraging signs of clinical efficacy were seen as two out of five evaluable patients achieved good response: one PR and one VGPR.

Results of operations, financial position and net assets

The Heidelberg Pharma Group, as of the reporting date consisting of Heidelberg Pharma AG and its three subsidiaries Heidelberg Pharma Research GmbH, HDP G250 AG & Co. KG, and HDP G250 Beteiligungs GmbH, reports consolidated figures. The two latter companies are not operationally active and affiliated to the parent company like Heidelberg Pharma Research GmbH.

The reporting period referred to below relates to the period from 1 December 2025 to 31 August 2026 (9M 2026).

In the first nine months of the 2026 financial year, the Group generated sales revenues and other income totaling EUR 11.5 million (previous year: EUR 6.4 million). This represents an increase of 79.4% and is in line with the planning. The sales revenues included in this figure rose from EUR 1.4 million the previous year to EUR 9.3 million due to milestone payments from partners. Other income amounted to EUR 2.2 million and was thus significantly lower than the previous year’s level of EUR 5.0 million – a figure that was largely driven by unrealized foreign exchange rate gains (EUR 3.4 million).

Operating expenses, including depreciation, decreased by 29.4% to EUR 19.9 million in the reporting period (previous year: EUR 28.2 million), reflecting the restructuring and disciplined cost management. Operating expenses are broken down as follows: Cost of sales increased to EUR 1.7 million (previous year: EUR 0.2 million) because of material deliveries to partners and corresponds to 9% of total costs. Research and development costs of EUR 13.3 million were significantly lower compared to last year (9M 2025: EUR 21.0 million). This decrease by 36.7% reflects the Company’s focus on the leading clinical program. R&D costs continue to represent the largest cost item, accounting for 67% of operating expenses. Administrative costs, which include the costs of holding activities, the stock exchange listing and the executive management board, decreased to EUR 4.3 million compared to the same period last year (EUR 5.0 million), which is mainly due to lower personnel costs. Administrative costs account for 21% of operating expenses. Other expenses for business development, marketing and commercial market supply activities, which mainly include personnel, but also expenses for exchange rate differences, decreased by more than half compared to the previous year from EUR 2.0 million to EUR 0.7 million and represented 3% of operating expenses.

The financial result, which is mainly made up of interest income on bank balances, amounted to EUR 0.2 million (previous year: EUR 0.7 million). The decrease is attributable to a lower investment volume and lower interest rates.

The net loss for the first nine months of the financial year decreased significantly to EUR 8.7 million compared to the previous year’s figure of EUR 21.1 million. This 58.8% improvement was mainly driven by higher revenues and lower operating expenses. Earnings per share improved accordingly from EUR -0.45 in the previous year to EUR -0.19 in the reporting period.

Cash amounted to EUR 19.8 million at the end of the third quarter (30 November 2025: EUR 15.0 million; 31 August 2025: EUR 22.9 million). Excluding financing effects (essentially HCRx/ Soleus Capital), Heidelberg Pharma recorded an average cash outflow of EUR 1.3 million per month in the first nine months of the fiscal year (previous year: EUR 2.8 million outflow).

Total assets as of 31 August 2026 amounted to EUR 42.8 million and were therefore above the figure at the comparative reporting date of 30 November 2025 (EUR 38.1 million). Equity decreased to EUR -19.3 million as a result of the loss for the period compared to the end of the 2025 financial year (EUR -10.9 million).

Financial outlook for 2026

Heidelberg Pharma confirms the full-year financial guidance issued on 26 March 2026.

The Executive Management Board expects the Heidelberg Pharma Group to generate between EUR 11.0 million and EUR 15.0 million in sales revenue and other income in the 2026 fiscal year.

Operating expenses are estimated between EUR 25.0 million and EUR 29.0 million. In addition, Heidelberg Pharma assumes that over the next few years total expenses will continue to exceed income.

If income and expenses develop as anticipated, the change in cash funds in the 2026 fiscal year for Heidelberg Pharma AG’s business operations is expected to remain stable or decline slightly compared to 2025 (EUR -14.4 million). The change in cash funds could therefore be in the range of EUR 0.0 million to EUR -4.0 million. Thus, the cash balance at the end of the 2026 fiscal year should amount to between EUR 11.0 million and EUR 15.0 million (2025: EUR 15.0 million).

The Group’s financing is secured at least until mid-2027 based on current internal planning.

The complete set of figures for the interim financial statements is available at http://www.heidelberg-pharma.com/ “Press & Investors > Announcements and Reports > Financial Reports > Interim announcement of 15 October 2026”. A conference call on this interim announcement will not be offered.

Key figures for the Heidelberg Pharma Group

In EUR thsd.	9M 2026 1 EUR thsd.	9M 2025 1 EUR thsd.
Earnings
Sales revenue	9,297	1,436
Other income	2,228	4,988
Operating expenses	(19,936)	(28,179)
of which research and development costs	(13,311)	(21,042)
Operating result	(8,411)	(21,756)
Earnings before tax	(8,251)	(21,054)
Net loss for the period / Comprehensive income	(8,676)	(21,054)
Basic earnings per share in EUR	(0.19)	(0.45)
Balance sheet as of the end of the period
Total assets	42,819	54,052
Cash	19,841	22,869
Equity	(19,323)	10,530
Equity ratio2 in %	(45.1)	19.5
Cash flow statement
Cash flow from operating activities	(12,360)	(24,818)
Cash flow from investing activities	682	(179)
Cash flow from financing activities	16,645	18,428
Cash flow from other matters	(103)	15.7
Employees (number)
Employees as of the end of the period3	35	126
Full-time equivalents as of the end of the period3	33	114

 

1 The reporting period begins on 1 December and ends on 31 August.
2 Equity / total assets
3 Including members of the Executive Management Board
Rounding of exact figures may result in differences.

Contact Heidelberg Pharma AG Sylvia Wimmer Senior Director Corporate Communications Tel.: +49 6203 1009 1004 Email: investors@hdpharma.com Wallstadter Straße 59, 68526 Ladenburg

IR/PR support MC Services AG Katja Arnold (CIRO) Managing Director & Partner Tel.: +49 89 210 228 40 Email: katja.arnold@mc-services.eu

About Heidelberg Pharma

Heidelberg Pharma is the first company to develop cancer therapies using Amanitin, a compound derived from the green death cap mushroom. The biological mechanism of action of the toxin represents a new therapeutic modality and is used as a compound in the Amanitin-based ADC technology, the so-called ATAC technology.

The lead candidate HDP-101 (INN: pamlectabart tismanitin) is a BCMA ATAC in clinical development for multiple myeloma. The candidate has been granted Orphan Drug Designation and Fast Track Designation from the FDA. A second ATAC candidate, HDP-102, is in clinical development stage in Non-Hodgkin Lymphoma. HDP-103 against metastatic castration-resistant prostate cancer and HDP-104 targeting gastrointestinal tumors such as colorectal cancer have completed preclinical development. These programs are available for partnering.

The company is based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at www.heidelberg-pharma.com/.

ATAC^® is a registered trademark of Heidelberg Pharma Research GmbH.

This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

Frauenfeld, 15 October 2026

Press release
Ad hoc announcement pursuant to Art. 53 LR

DocMorris accelerates Rx growth to 78% in Q3; EBITDA breakeven already achieved in Q3 and revenue and EBITDA forecast for 2026 raised again

• Revenue growth of 21.5% in Q3 and 15.5% in the first nine months
• Strong acceleration of Rx growth to 78.3% versus Q3 2025; plus 33.5% versus Q2 2026
• Non-Rx up 5.5% in Q3, of which Digital Services up 46.1%
• Adjusted EBITDA of CHF 0.6 million in Q3
• Revenue and adjusted EBITDA guidance for 2026 increased

CEO Walter Hess says: “Our revenue growth accelerated again in the third quarter of 2026, demonstrating that our offering is well received by patients. We will continue to consistently leverage this Rx momentum to expand our customer base and further solidify our position in the digital healthcare market.”

CFO Daniel Wüest adds: “Thanks to the strong performance of Rx and Digital Services, as well as further improvements in cost and marketing efficiency, we already achieved our targeted EBITDA breakeven in the third quarter with adjusted EBITDA of CHF 0.6 million. Against this backdrop, we are once again raising our revenue and EBITDA guidance for the full year.”

Significantly accelerated Rx growth in the third quarter

• DocMorris increased its external revenue[1] in the third quarter of 2026 significantly by 21.5 per cent[2] year-on-year to CHF 342.7 million, while revenue increased by 22.2 per cent to CHF 327.4 million.
• In the segment Germany, external revenue increased by 22.0 per cent.
• External revenue growth for prescription medicines (Rx) accelerated in the third quarter to 78.3 per cent year-on-year; Rx external revenue was 33.5 per cent higher than in the already strong second quarter of 2026 (up 17.0 per cent in Q2 compared to Q1 2026).
• Non-Rx[3] external revenue increased by 5.5 per cent.
• The OTC business grew as planned by 3.5 per cent.
• Digital Services, comprising TeleClinic, Retail Media and Marketplace, achieved revenue growth of 46.1 per cent to CHF 13.9 million, with a further increase in earnings contribution.
• In the segment Europe, revenue increased by 12.0 per cent.
• The number of active customers[4] increased year-on-year by 1.5 million to 13.1 million. Of these, 0.2 million were added in the third quarter of 2026, with the number of new Rx customers increasing at an above-average rate.
• DocMorris achieved an adjusted EBITDA of CHF 0.6 million in the third quarter, thus reaching the targeted breakeven ahead of schedule.

Continued double-digit growth in the first nine months

• External revenue increased by 15.5 per cent to CHF 970.6 million in the first nine months of 2026 year-on-year, while revenue increased by 16.4 per cent to CHF 926.6 million.
• In the segment Germany, external revenue increased by 16.0 per cent.
• Rx growth amounted to 52.6 per cent in the first nine months, with a continued positive trend in the fourth quarter.
• Non-Rx increased by 6.2 per cent, with Digital Services growing by 62.0 per cent to CHF 41.0 million.
• In the segment Europe, revenue increased by 6.3 per cent.

In September 2026, DocMorris successfully repurchased its CHF 49.6 million convertible bond maturing in 2028. The repurchase was financed by issuing a new convertible bond maturing in 2031. This move extends the company’s maturity profile while simultaneously reducing its relative financing costs.

Outlook
Due to continued positive current trading, DocMorris is raising its guidance for 2026 again as follows:

• External revenue growth: 12.5 to 15 per cent (previously: 9 to 13 per cent);
• Adjusted EBITDA: Better than minus CHF 10 million (previously: minus CHF 10 million to minus CHF 17.5 million);
• Capital expenditure remains unchanged at below CHF 30 million.

Management confirms the target of achieving free cash flow breakeven during 2027, following the achievement of the adjusted EBITDA breakeven target during 2026 in the third quarter. Medium-term targets remain unchanged.

 

Key figures, in million CHF (unaudited)	Q3 2026	Q3 2025	Change	Change in local currency
DocMorris external revenue	342.7	282.3	21.4%	21.5%
DocMorris revenue	327.4	268.1	22.1%	22.2%
Markets
Germany external revenue	326.3	267.6	21.9%	22.0%
Germany revenue	311.0	253.5	22.7%	22.8%
Germany Rx external revenue	108.1	60.9	77.6%	78.3%
Germany non-Rx external revenue	218.2	206.8	5.5%	5.5%
Europe revenue	16.4	14.6	11.9%	12.0%

 

Key figures, in million CHF (unaudited)	9M 2026	9M 2025	Change	Change in local currency
DocMorris external revenue	970.6	854.3	13.6%	15.5%
DocMorris revenue	926.6	809.4	14.5%	16.4%
Markets
Germany external revenue	920.3	806.2	14.1%	16.0%
Germany revenue	876.4	761.3	15.1%	17.0%
Germany Rx external revenue	256.0	170.5	50.1%	52.6%
Germany non-Rx external revenue	664.2	635.7	4.5%	6.2%
Europe revenue	50.3	48.1	4.6%	6.3%

 

Investors and analyst contact
Kelvin Jörn, Head of Investor Relations
Email: ir@docmorris.com, phone: +41 52 560 58 10

Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1

Agenda

12 November 2026	Capital Markets Day in Heerlen (NL)
19 January 2027	Revenue 2026
18 March 2027	2026 Full-year results and outlook 2027 (hybrid/Zurich, conference call/webcast)
15 April 2027	Q1/2027 Trading Update
12 May 2027	Annual General Meeting, Zurich

 

DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, telemedicine and marketplace with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands. TeleClinic is Germany’s largest telemedicine platform, connecting patients with more than 6,500 doctors. DocMorris operates leading marketplaces for health and personal care products in Southern Europe. With its broad range of products and services, DocMorris is pursuing its vision of becoming the leading digital health companion for everyone to manage their health in one click. Around 1,600 employees in Germany, the Netherlands, Spain, France, Portugal and Switzerland generated an external revenue of CHF 1,186 million serving over 12 million active customers in 2025. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.

Disclaimer
This announcement contains certain forward-looking statements about DocMorris AG and its business, either explicitly or implicitly. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results, financial position, performance or achievements of DocMorris AG to differ materially from the future results, performance or achievements expressed or implied by such forward-looking statements. DocMorris AG is making this announcement available as of today’s date and undertakes no obligation to update the forward-looking statements contained herein as a result of new information, future events or for any other reason.

 

 

^[1] External revenue consists of the revenue of DocMorris plus online revenue of apotal, less revenue related to supplies to apotal.

^[2] All percentages are in local currency.

^[3] Consisting of OTC business and Digital Services (TeleClinic, Retail Media, Marketplace).

^[4] Customers supplied by DocMorris, either directly or through its partners.

Ad-hoc notification in accordance with Sec. 17 of the MAR

Drägerwerk AG & Co. KGaA: Preliminary figures Q3 2026: Earnings below prior year – net sales up – forecast confirmed

Lübeck, October 14, 2026 – Based on preliminary calculations, Dräger generated earnings before interest and taxes (EBIT) of around EUR 48 million in the third quarter of 2026 (Q3 2025: EUR 56.7 million). This includes customs duty refunds of EUR 20.1 million. The EBIT margin came to around 5.6 percent (Q3 2025: 6.8 percent).

The lower net sales growth in the third quarter of 2026 was offset by a disproportionate increase in functional expenses. At the same time, the comparison base was high: In the third quarter of 2025, EBIT more than doubled due to significant net sales growth driven by catch-up effects and moderate cost development.

Net sales increased by 1.0 percent (net of currency effects; nominal: 2.1 percent) to around EUR 851 million in the third quarter of 2026 (Q3 2025: EUR 833.3 million). Net sales in the safety division rose by 4.1 percent (net of currency effects; nominal: 5.3 percent) to around EUR 381 million (Q3 2025: EUR 362.0 million). In the medical division, net sales declined by 1.4 percent (net of currency effects; nominal: -0.4 percent) to around EUR 469 million, ending slightly below the prior-year level (Q3 2025: EUR 471.3 million). The Group’s gross margin increased to around 47.5 percent (Q3 2025: 45.6 percent). The main reason for this was the customs duty refunds.

Order intake rose by 7.0 percent (net of currency effects; nominal: 8.2 percent) to around EUR 926 million (Q3 2025: EUR 856.1 million). The main growth driver was safety, with a strong increase of 20.2 percent (net of currency effects; nominal: 21.7 percent) to around EUR 452 million (Q3 2025: EUR 371.4 million). This development was due in particular to high demand in the regions Germany, Americas, and Asia-Pacific. In medical, order intake fell by 3.0 percent (net of currency effects; nominal: -2.2 percent) to around EUR 474 million (Q3 2025: EUR 484.7 million).

Business performance in the first nine months of 2026
In the first nine months, order intake of around EUR 2,674 million was 3.6 percent (net of currency effects; nominal: 3.1 percent) above the prior-year figure (9 months 2025: EUR 2,594.1 million). The safety division recorded significant growth of 13.1 percent (net of currency effects; nominal: 13.1 percent) to around EUR 1,243 million, thanks to overall very good demand (9 months 2025: EUR 1,098.6 million). In the medical division, order intake decreased by 3.5 percent (net of currency effects; nominal: -4.3 percent) to around EUR 1,431 million (9 months 2025: EUR 1,495.5 million). The main reason for this was the major order from Mexico for hospital infrastructure systems in the second quarter of 2025. Adjusted for this effect, order intake in medical would have increased slightly (net of currency effects) in the first nine months of 2026.

Net sales rose by 5.3 percent (net of currency effects; nominal: 4.7 percent) to around EUR 2,454 million (9 months 2025: EUR 2,343.5 million). Both divisions contributed to this increase: The safety division recorded growth of 6.5 percent (net of currency effects; nominal: 6.4 percent) to around EUR 1,087 million (9 months 2025: EUR 1,021.2 million), while medical recorded an increase of 4.4 percent (net of currency effects; nominal: 3.4 percent) to around EUR 1,367 million (9 months 2025: EUR 1,322.3 million). The Group’s gross margin went up to around 46.8 percent (9 months 2025: 45.1 percent).

EBIT increased by almost half to around EUR 112 million (9 months 2025: EUR 77.1 million). The EBIT margin also improved significantly to around 4.6 percent (9 months 2025: 3.3 percent). EBIT included one-off effects of EUR 27.9 million from refunded customs duties. Of this amount, EUR 7.8 million was attributable to the second quarter and EUR 20.1 million to the third quarter. Part of these refunds – EUR 3.8 million in total – relates to customs payments from the current fiscal year and is therefore recognized with no impact on earnings.

Forecast for 2026
Dräger confirms its forecast for the current fiscal year and continues to expect an increase in net sales of 2.0 to 6.0 percent (net of currency effects) and an EBIT margin of 6.0 to 8.0 percent.

The quarterly statement will be published on October 29, 2026.

 

Drägerwerk AG & Co. KGaA
Moislinger Allee 53–55
23558 Lübeck, Germany
www.draeger.com

 

Investor Relations:
Thomas Fischler
Tel. +49 451 882-2685
thomas.fischler@draeger.com

 

Corporate Communications:
Ulrike Abratis
Tel. +49 451 882-3202
ulrike.abratis@draeger.com

 

Disclaimer
This ad hoc report contains statements on the future development of Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to date. They were compiled to the best of the company’s knowledge. Dräger does not provide any warranty nor assume any responsibility for the future developments and results described above. These are dependent on a number of factors. They entail various risks and contingencies outside of the company’s influence and are based on assumptions which could prove to be incorrect. Dräger does not assume any responsibility for updating the forward-looking statements contained in this report. This does not infringe any legal stipulations on the adjustment of forecasts. Please go to Investor Relations / Definitions of financial indicators at www.draeger.com for information on alternative performance measures used.

Change in Top Management
Jean-Marc Bellaiche to become new CEO of the DOUGLAS Group – Sander van der Laan to retire

Düsseldorf, 14 October 2026 – Jean-Marc Bellaiche will become the new Chief Executive Officer (CEO) of Europe’s leading premium beauty retailer, the DOUGLAS Group. He succeeds Sander van der Laan, who, after a career of 36 years in the international retail business including four years with the DOUGLAS Group, has decided to retire as an executive. The Supervisory Board of Douglas AG today appointed Jean-Marc Bellaiche as CEO with effect from 1 November 2026 for a term of four years.

“This important change in the leadership at the top of the company has been prepared very thoughtfully and carefully, ensuring a smooth and professional transition”, said Dr. Henning Kreke, Chairman of the Supervisory Board of the Douglas AG. “We truly regret Sander van der Laan’s decision to retire, while fully respecting his choice after a long and successful career. With his departure, the DOUGLAS Group loses an outstanding leader and highly experienced retail executive who has played a pivotal role in the successful development of the Group. At the same time, we are very pleased to have appointed Jean-Marc Bellaiche, a highly experienced executive in international retail and luxury, with a strong track record across beauty, premium department stores, digital transformation, brand building and strategy. We are convinced that he will build on the progress already made and put even more focus on customer-centricity, beauty brand partnerships and operational excellence.”

“I would like to thank the Supervisory Board of the Douglas AG for the confidence it has placed in me”, said Bellaiche. “I am particularly excited to join the Group at such an important moment in the evolution of the beauty industry. The DOUGLAS Group plays a leading role in the European premium beauty market and has a manifold of unique assets, including an outstanding omnichannel footprint, a large base of loyal customers, and an attractive assortment based on close relationships with beauty brands. I look forward to building on these strengths together with the management team and all my colleagues across 22 European countries, while driving the innovations and changes needed to succeed in a rapidly changing market environment.”

Van der Laan said: “I am incredibly grateful for my time at the DOUGLAS Group. I have met many inspiring people, learned a great deal about premium beauty, and, together with around 20,000 colleagues, we have made significant progress. The decision to step down was not an easy one for me. But after a 36-year career, including senior leadership roles at highly respected retail companies in Europe and the United States, I feel that the time is right to retire from executive management. This is the right moment to hand over the reins to someone who can bring fresh thinking and new ideas.”

The 56 year old Frenchman Bellaiche began his career at Boston Consulting Group in 1993, where he eventually became Managing Director and Global Leader of the Luxury, Fashion and Beauty sector. In 2014, he joined Tiffany & Co. as Senior Vice President and member of the Executive Committee. He subsequently held senior leadership and board positions in the technology companies Contentsquare and Arianee. After spending a decade in the United States, he moved back to Europe in 2020 to become CEO of Printemps Group, which includes the iconic French department store chain. During his five-year mandate, he strengthened Printemps’s distinctiveness and customer-centricity, introduced more exclusivities in the assortment, accelerated its international and omnichannel development, and improved the operating profitability. For the last year, he served as CEO of the luxury resort operator Sani/Ikos Group.

Sander van der Laan joined the DOUGLAS Group in October 2022. Since then, he has successfully driven the transformation of the Düsseldorf-based company into a true omnichannel business and implemented significant strategic, operational, and structural improvements. Among his key achievements are a new category and exclusive-brands strategy and a comprehensive update of the store-format and -network strategy. He also comprehensively reorganized the Group‘s supply chain, further developed the digital platforms, implemented a comprehensive ESG strategy, and harmonized internal processes and structures. In 2024, the company was listed on the stock exchange. Van der Laan has also been deeply committed to further developing the corporate culture and introduced the purpose ‘Make life more beautiful’.

Dr. Kreke said: “On behalf of the entire Supervisory Board, I would like to thank Sander van der Laan for his outstanding achievements and dedication to the company. We wish him all the best for this new chapter in his life. We also wish Jean-Marc Bellaiche a successful start in his new role at the DOUGLAS Group and look forward to working with him as he leads the company together with CFO Marco Giorgetta, the entire management team and all employees into its next phase of development.”

About the DOUGLAS Group

The DOUGLAS Group, with its commercial brands DOUGLAS, NOCIBÉ, Parfumdreams and Niche Beauty, is the number one omnichannel premium beauty destination in Europe. The DOUGLAS Group is inspiring customers to live their own kind of beauty by offering a unique assortment online and in around 1,970 stores. With unparalleled size and access to customers, the DOUGLAS Group is the partner of choice for brands and offers a premium range of selective and exclusive brands as well as own corporate brands. The assortment includes fragrances, color cosmetics, skin care, hair care, accessories as well as beauty services. Strengthening its successful omnichannel positioning while consistently developing superior customer experience is at the heart of the DOUGLAS Group strategy “Let it Bloom”. The winning business model is underpinned by the Group’s omnichannel proposition, leading brands, and data capabilities. In the financial year 2024/2025, the DOUGLAS Group generated sales of 4.58 billion euros and employed more than 19,900 people across Europe. The DOUGLAS Group (Douglas AG) is listed at the Frankfurt Stock Exchange.

For further information please visit the DOUGLAS Group Website.

Presse Contact

Peter Wübben
SVP Group Communications & Sustainability
Phone: +49 211 16847 6644
Mail: newsroom@douglas.de

Investor Contact

Dafne Sanac
Director / Senior Principal Investor Relations

Phone: +49 151 55675545
E-Mail: ir@douglas.de

Düsseldorf, 14 October 2026 – The Supervisory Board of Douglas AG today resolved to appoint Jean-Marc Bellaiche as a member of the Management Board and Chief Executive Officer (CEO) of Douglas AG with effect from 1 November 2026. The appointment is for a term of four years. Mr. Bellaiche succeeds Alexander van der Laan, who has decided to retire from active management. Mr. van der Laan will resign from his office as member and Chief Executive Officer of the Management Board by mutual agreement with the Supervisory Board with effect from 31 October 2026.